Advertisement

SAN DIEGO, July 27 /PRNewswire/ -- Millennium Laboratories, Inc., a national, research-based medication monitoring company specifically focused on clinicians who treat chronic pain, strongly advocated for an increase in physician reimbursement for point-of-care urine drug screening at the Annual Clinical Laboratory Public Meeting of the Centers for Medicare and Medicaid Services (CMS) on July 22, 2010. As the only therapeutic drug monitoring company presenting, Millennium was continuing its advocacy campaign, launched in June of 2009, supporting fair reimbursement for point-of-care (POC) urine drug screen devices.

James Slattery, Millennium Laboratories founder and CEO, explained the company's presence at the meeting. "We are advocating for a higher, though moderate, reimbursement level to physicians for performing drug screening tests. Millennium as a corporation has no financial stake in this argument. It is simply the right thing to do for all parties involved."

In 2009 CMS drastically cut reimbursement for point-of-care test (POCT) devices used in urine drug screening. Millenni

'/>"/>

SOURCE

Advertisement
Advertisement